

June, 3 2019

To the press and whom it may concern,

Company name: CMIC HOLDINGS Co., Ltd.
 Representative: Kazuo Nakamura, Representative Director and CEO
 (TSE 1st Section Code No. 2309)
 Inquiries: Wataru Mochizuki, Corporate Director and CFO
 (Phone: +81-3-6779-8000)

**Completion of Transfer of a Subsidiary (Sub-subsidiary)
 (Update on Previously Disclosed Transaction)
 -Completion of assignment of Nishine Plant from Astellas Pharma
 Tech by CMIC CMO-**

As disclosed in "Announcement on transfer of a Subsidiary (Sub-subsidiary)-Assignment of Nishine Plant from Astellas Pharma Tech Co., Ltd. by CMIC CMO-" on December 21, 2018, CMIC CMO Co., Ltd., a consolidated subsidiary of CMIC HOLDINGS Co., Ltd., operating a CDMO (Contract Development and Manufacturing Organization) business has completed the stock transfer procedure with Astellas Pharma Tech Co., Ltd. as of June 1, 2019, and CMIC HOLDINGS Co., Ltd. hereby announces that CMIC CMO Nishine Co., Ltd. (A successor company of Nishine Plant business) has become a subsidiary (Sub-subsidiary) of CMIC HOLDINGS Co., Ltd..

This change should have an immaterial impact on financial statements (the fiscal year ending September 30, 2019).

Overview of Transferred Subsidiary (Sub-subsidiary)

(1) Name	CMIC CMO NISHINE Co., Ltd.
(2) Location	Obuke 2-154-13, Hachimantai-city, Iwate
(3) Representative	Representative Director, Motoyoshi Katano
(4) Operations	Manufacturing of pharmaceutical products
(5) Capital	¥100 million
(6) Date of establishment	January 17, 2019
(7) Major shareholders and shareholding ratio	CMIC CMO Co., Ltd. (Shareholding ratio: 100%)